ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer

This study has been terminated.
(Lack of accrual)
Sponsor:
Collaborators:
Novartis
Board of Regents, State of Louisiana
Information provided by:
Tulane University Health Sciences Center
ClinicalTrials.gov Identifier:
NCT00993642
First received: October 9, 2009
Last updated: July 20, 2011
Last verified: September 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2010
  Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)